Rare diseases
Investigational molecules
Locations
Recruiting trials first
5 clinical trials in this condition
France
Italy
BelgiumFranceIn short
Pericarditis treatment focuses on reducing inflammation and pain, preventing recurrence, and protecting the heart from serious complications. The approach to managing this condition has evolved, with both established medications and new therapies offering hope to patients dealing with this often frustrating illness.
When someone is diagnosed with pericarditis, the main goals of treatment are to calm the inflammation in the pericardium (the protective sac surrounding the heart), relieve chest pain, and prevent the condition from coming back. The treatment plan depends heavily on whether this is the first episode or if the condition keeps returning, which happens in up to 30% of patients after their initial bout.
Not everyone with pericarditis needs the same treatment. Some people experience mild symptoms that improve with rest and basic medications, while others face severe or repeated episodes that require more aggressive approaches. The severity of symptoms, the presence of complications like fluid buildup around the heart, and how well initial treatments work all influence what doctors recommend next.
Treatment decisions also consider the underlying cause when one can be identified. In many cases in North America and Western Europe, doctors cannot pinpoint exactly what triggered the pericarditis—these cases are called idiopathic. When a viral infection, autoimmune disease, or other specific cause is found, treating that underlying condition becomes part of the overall plan.
Medical societies have established guidelines to help doctors provide consistent, evidence-based care. These recommendations continue to evolve as researchers learn more about which treatments work best and which patients need more intensive monitoring. The goal is always to help patients return to normal activities as safely and quickly as possible while minimizing the risk of future flare-ups.
The foundation of pericarditis treatment typically involves nonsteroidal anti-inflammatory drugs, commonly called NSAIDs. These medications work by blocking the body's production of chemicals that cause inflammation and pain. Commonly prescribed NSAIDs include ibuprofen and aspirin, which patients usually take at high doses for a period of time before gradually tapering down as symptoms improve.
Alongside NSAIDs, doctors now strongly recommend colchicine as part of first-line therapy. This medication has become a cornerstone of treatment because research shows it helps prevent pericarditis from coming back. Colchicine works differently than NSAIDs—it reduces inflammation by affecting how certain white blood cells behave. For a first episode of pericarditis, colchicine is typically prescribed for three months. If the condition recurs, treatment may extend to six to twelve months.
The combination of an NSAID and colchicine forms the standard approach for most patients with acute pericarditis. This pairing addresses both immediate symptom relief and longer-term prevention. Doctors start with high doses to control active inflammation, then carefully reduce the dosage over time while monitoring how well symptoms respond and checking blood tests that measure inflammation levels.
When NSAIDs and colchicine don't provide enough relief, or when certain conditions make these drugs unsuitable, doctors may turn to corticosteroids such as prednisone. These powerful anti-inflammatory medications can quickly reduce swelling and pain. However, they come with important considerations. Steroids can trigger rebound flare-ups when stopped too quickly, so they must be tapered very slowly and carefully. Long-term use carries risks including weight gain, elevated blood sugar, weakened bones, and increased infection risk.
Because of these concerns, steroids are traditionally reserved for patients who don't respond to standard treatment, those with severe disease, or cases where pericarditis stems from certain autoimmune conditions or kidney failure. When prescribed, doctors use the lowest effective dose and monitor patients closely for side effects.
The typical duration of treatment for a first episode of acute pericarditis ranges from several weeks to three months, depending on how quickly symptoms resolve. Doctors monitor progress through follow-up appointments, checking for improvement in chest pain, normalization of blood tests that measure inflammation (such as C-reactive protein), and absence of fluid buildup around the heart on imaging studies.
Side effects from these standard treatments can occur. NSAIDs may cause stomach upset, ulcers, kidney problems, or increased bleeding risk. Colchicine commonly causes diarrhea and stomach discomfort, especially at higher doses. Patients taking these medications need to report any concerning symptoms to their doctor, who may adjust dosages or switch to alternative approaches.
In cases where the pericardium fills with excessive fluid—a complication called pericardial effusion—and this fluid puts dangerous pressure on the heart, a procedure called pericardiocentesis may be necessary. During this procedure, a doctor inserts a needle through the chest wall to drain the accumulated fluid, relieving pressure and allowing the heart to function normally again.
For chronic cases where the pericardium becomes thick, scarred, and constricts the heart—known as constrictive pericarditis—surgery may become necessary. The surgical procedure, called pericardiectomy, involves removing part or all of the scarred pericardium. This is typically considered only when symptoms significantly impact a patient's quality of life and medications haven't helped.
For patients whose pericarditis keeps returning despite standard treatments, new therapeutic options have emerged from clinical research. The most significant advancement involves medications that target a specific inflammatory pathway in the body. These drugs, called IL-1 inhibitors, work by blocking interleukin-1, a protein that plays a key role in the inflammatory process that attacks the pericardium in recurrent cases.
The first medication in this class to receive approval from the U.S. Food and Drug Administration for recurrent pericarditis is called Arcalyst (rilonacept). This approval came in 2021, marking a major milestone because it was the first therapy specifically approved for treating recurrent pericarditis in people 12 years and older. Before this, no medications had been officially approved by the FDA specifically for this frustrating condition.
IL-1 inhibitors represent a different approach compared to traditional anti-inflammatory medications. Rather than broadly suppressing inflammation throughout the body, these drugs target the specific biological mechanism that causes repeated pericarditis flares. By blocking the interleukin-1 pathway, they help prevent the abnormal inflammatory response that keeps attacking the pericardium even when there's no active infection or clear trigger.
Clinical trials testing these IL-1 inhibitor medications have shown promising results. Patients who had struggled with frequent, painful recurrences despite trying multiple standard treatments experienced significant improvement when given these newer drugs. Many saw a reduction in the number of flares, less severe chest pain during episodes, and an improved ability to participate in daily activities without constant fear of another attack.
According to updated guidance released in 2025 by the American College of Cardiology, IL-1 inhibitors are now recommended when first-line treatments (NSAIDs and colchicine) fail to control symptoms or when patients cannot tolerate steroids. This represents an important shift in how doctors approach difficult-to-treat cases. The new guidelines emphasize that these targeted therapies offer an alternative to long-term steroid use, which carries considerable side effects.
These medications are typically administered through injection, and treatment duration varies depending on individual response. Because they are newer, they are generally reserved for patients with recurrent pericarditis rather than those experiencing a first episode. Doctors carefully select which patients might benefit most from this approach based on their history, previous treatment responses, and overall health status.
Research into IL-1 inhibitors continues, with ongoing studies exploring optimal dosing strategies, treatment duration, and long-term safety. Scientists are particularly interested in identifying which patients are most likely to benefit from these targeted therapies, so treatment can be personalized more effectively. Some studies are examining whether earlier use of IL-1 inhibitors might prevent the development of chronic or constrictive forms of the disease.
Clinical trials for pericarditis treatments are conducted at major medical centers across the United States, Europe, and other regions. Patients interested in participating in these studies typically need to meet specific criteria, such as having experienced a certain number of recurrent episodes or having failed to respond to standard medications. Participation in clinical trials gives patients access to cutting-edge therapies while helping researchers gather important information about safety and effectiveness.
The development of these newer therapies represents part of a broader trend in medicine toward precision approaches that target specific molecular pathways responsible for disease. For pericarditis patients who have endured years of recurrent pain, emergency room visits, and inability to work or enjoy normal activities, these advances offer genuine hope for better disease control and improved quality of life.
Beyond IL-1 inhibitors, researchers continue investigating other potential therapeutic targets. Studies are examining how the immune system behaves in patients with recurrent pericarditis, looking for additional pathways that might be manipulated to prevent flares. Some research focuses on better understanding why certain patients develop recurrent disease while others have only a single episode, with the goal of developing predictive tests and preventive strategies.
The safety profile of IL-1 inhibitors appears favorable based on clinical trial data, though as with any medication, side effects can occur. Common issues include injection site reactions and an increased risk of upper respiratory infections. Because these drugs affect the immune system, patients taking them require monitoring for infections and other potential complications. Long-term safety data continues to accumulate as more patients use these medications over extended periods.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
